Dosing & administration for migraine

For your patients with migraine,

Emgality comes in an easy-to-use pen for self-administration1,2

Emgality Pen data image
Emgality Pen data image

aPatient- and caregiver-rated experiences with the pen were assessed in an open-label, 12-month study. A total of 84 patients who received once-monthly injections of Emgality 120 mg completed a questionnaire that included ratings of the medication delivery device’s overall ease of use and the respondents’ confidence in their ability to use the device.3


Recommended dosing with no titration required1a

Dosing of Emgality pen for first month and subsequent months

aThe Emgality Pen needle is 27 gauge x 1/2 inch.4



Steady-state concentration image

CGRP=calcitonin gene-related peptide.

SELECT IMPORTANT SAFETY INFORMATION
Contraindications

Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

Discover how eligible patients can get Emgality for as little as $0 for up to 12 monthsa

Instructions on how to prescribe Emgality using an Electronic Health Record (EHR) system are available.

aTerms and Conditions: Offer good until 12/31/2021 for up to 12 months of Emgality. Patients with commercial drug insurance may be able to pay as little as $0 for their first fill of Emgality. For the 2nd and subsequent fills, patients must have coverage for Emgality through their commercial drug insurance plan to continue to pay as little as $0 per fill. Offer subject to a monthly savings of wholesale acquisition cost plus usual and customary pharmacy charges and a separate $4900 maximum annual savings. Participation in the program requires a valid patient HIPAA authorization. Patient is responsible for any applicable taxes, fees, or amounts exceeding monthly or annual caps. This offer is invalid for patients without commercial drug insurance or those whose prescription claims are eligible to be reimbursed, in whole or in part, by any governmental program, including, without limitation, Medicaid, Medicare, Medicare Part D, Medigap, DoD, VA, TRICARE®/CHAMPUS, or any state patient or pharmaceutical assistance program. Offer void where prohibited by law and subject to change or discontinue without notice. Card activation is required. Subject to additional terms and conditions, which can be found here.


References: 1. Emgality [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC. 2. Data on File. Lilly USA, LLC. DOF-GZ-US-0013. 3. Data on File. Lilly USA, LLC. DOF-GZ-US-0020. 4. Data on File. Lilly USA, LLC. DOF-GZ-US-0060. 5. Aimovig [Prescribing Information]. Thousand Oaks, CA: Amgen Inc.; 2019. 6. Ajovy [Prescribing Information]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; 2019. 7. Emgality [Instructions for Use]. Indianapolis, IN: Lilly USA, LLC.

Indications and Important Safety Information
Indications

Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated in adults for the:

  • Preventive treatment of migraine
  • Treatment of episodic cluster headache

Important Safety Information

CONTRAINDICATIONS
Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.


WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions
Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.


ADVERSE REACTIONS
The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.


Please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the device.


GZ HCP ISI 10DEC2019